Antisense Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report, Analysis Report By By ASO Generation (First-Generation, Second-Generation, Third-Generation, Next-Generation), By Phase of Development, By Route of Administration, By Type of Therapy, By Indications, and By Drug Type, By Region, Forecasts, 2025-2034

Report Id: 1245 Pages: 180 Last Updated: 24 March 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Antisense Oligonucleotide Therapeutics Market-

Antisense Oligonucleotides Therapeutics Market By Type of Therapy

  • Monotherapy
  • Combination Therapy
  • Both

antisense oligonucliotide

Antisense Oligonucleotides Therapeutics Market By ASO Generation

  • First-Generation
  • Second-Generation
  • Third-Generation
  • Next-Generation

Antisense Oligonucleotides Therapeutics Market By Phase of Development

  • Commercial
  • Clinical
  • Preclinical
  • Discovery Stage

Antisense Oligonucleotides Therapeutics Market By  Route of Administration

  • Subcutaneous
  • Intravenous
  • Intrathecal
  • Intravitreal
  • Others

Antisense Oligonucleotides Therapeutics Market By Indications

  • Duchenne Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Transthyretin Amyloidosis
  • Familial Chylomicronemia Syndrome
  • Amyotrophic Lateral Sclerosis
  • Others

Antisense Oligonucleotides Therapeutics Market By Drug Type

  • Eleplinsen
  • Nusinersen
  • Inotersen
  • Volanesorsen
  • Golodirsen
  • Viltolarsen
  • Casimersen
  • Tofersen
  • Others

Antisense Oligonucleotides Therapeutics Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Antisense Oligonucleotides Market Snapshot

Chapter 4.          Global Antisense Oligonucleotides Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Opportunities

4.5.        Trends

4.6.        Investment and Funding Analysis

4.7.        Industry Analysis – Porter’s Five Forces Analysis

4.8.        USFDA Approved Antisense Oligonucleotide Products

4.9.        Clinical Trial Analysis

4.10.     Key Merger & Acquisitions, Partnership in the Market

4.11.     Competitive Landscape & Market Share Analysis

4.12.     Impact of Covid-19 Analysis

Chapter 5.          Market Segmentation 1: By Type of Therapy, Estimates & Trend Analysis

5.1.        By Type of Therapy, & Market Share, 2024 & 2034

5.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type of Therapy:

5.2.1.    Monotherapy

5.2.2.    Combination Therapy

5.2.3.    Both

Chapter 6.          Market Segmentation 2: By Route of Administration Estimates & Trend Analysis

6.1.        By Route of Administration & Market Share, 2024 & 2034

6.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:

6.2.1.    Subcutaneous

6.2.2.    Intravenous

6.2.3.    Intrathecal

6.2.4.    Intravitreal

6.2.5.    Others

Chapter 7.          Market Segmentation 3: By Phase of Development Estimates & Trend Analysis

7.1.        By Phase of Development & Market Share, 2024 & 2034

7.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Phase of Development:

7.2.1.    Commercial

7.2.2.    Clinical

7.2.3.    Preclinical

7.2.4.    Discovery Stage

Chapter 8.          Market Segmentation 4: By ASO Generation Estimates & Trend Analysis

8.1.        By ASO Generation & Market Share, 2024 & 2034

8.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By ASO Generation:

8.2.1.    First-Generation

8.2.2.    Second-Generation

8.2.3.    Third-Generation

8.2.4.    Next-Generation

Chapter 9.          Market Segmentation 5: By Drug Type Estimates & Trend Analysis

9.1.        By Drug Type & Market Share, 2024 & 2034

9.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Type:

9.2.1.    Eleplinsen

9.2.2.    Nusinersen

9.2.3.    Inotersen

9.2.4.    Volanesorsen

9.2.5.    Golodirsen

9.2.6.    Viltolarsen

9.2.7.    Casimersen

9.2.8.    Tofersen

9.2.9.    Others

Chapter 10.        Market Segmentation 6: By Indication Estimates & Trend Analysis

10.1.     By Indication & Market Share, 2024 & 2034

10.2.     Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:

10.2.1.  Duchenne Muscular Dystrophy

10.2.2.  Spinal Muscular Atrophy

10.2.3.  Transthyretin Amyloidosis

10.2.4.  Familial Chylomicronemia Syndrome

10.2.5.  Amyotrophic Lateral Sclerosis

10.2.6.  Others

Chapter 11.        Antisense Oligonucleotides Market Segmentation 7: Regional Estimates & Trend Analysis

11.1.     North America

11.1.1.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034

11.1.2.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034

11.1.3.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034

11.1.4.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034

11.1.5.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034

11.1.6.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034

11.1.7.  North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034

11.1.7.1.             U.S.

11.1.7.2.             Canada

11.2.     Europe

11.2.1.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034

11.2.2.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034

11.2.3.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034

11.2.4.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034

11.2.5.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034

11.2.6.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034

11.2.7.  Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034

11.2.7.1.             Germany

11.2.7.2.             U.K.

11.2.7.3.             France

11.2.7.4.             Italy

11.2.7.5.             Spain

11.2.7.6.             Rest of Europe

11.3.     Asia Pacific

11.3.1.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034

11.3.2.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034

11.3.3.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034

11.3.4.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034

11.3.5.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034

11.3.6.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034

11.3.7.  Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034

11.3.7.1.             Japan

11.3.7.2.             China

11.3.7.3.             India

11.3.7.4.             Australia

11.3.7.5.             South Korea

11.3.7.6.             Southeast Asia

11.3.7.7.             Hong Kong

11.3.7.8.             Rest of Asia Pacific

11.4.     Latin America

11.4.1.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034

11.4.2.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034

11.4.3.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034

11.4.4.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034

11.4.5.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034

11.4.6.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034

11.4.7.  Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034

11.4.7.1.             Brazil

11.4.7.2.             Mexico

11.4.7.3.             Rest of Latin America

11.5.     Middle East & Africa

11.5.1.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034

11.5.2.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034

11.5.3.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034

11.5.4.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034

11.5.5.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034

11.5.6.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034

11.5.7.  Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034

11.5.7.1.             GCC Countries

11.5.7.2.             South Africa

11.5.7.3.             Rest of MEA

Chapter 12.        Competitive Landscape

12.1.     Major Mergers and Acquisitions/Strategic Alliances

12.2.     Company Profiles

12.2.1.  Sarepta Therapeutics

12.2.2.  Biogen

12.2.3.  Alnylam Pharmaceuticals, Inc

12.2.4.  Antisense Therapeutics Limited

12.2.5.  Sarna Therapeutics GmbH

12.2.6.  Arrowhead Pharmaceuticals, Inc.

12.2.7.  Atlantic Pharmaceuticals, Inc.

12.2.8.  Enzo Pharmaceuticals, Inc.

12.2.9.  Bio-Path Holdings, Inc.

12.2.10.              Gene Signal International SA

12.2.11.              GlaxoSmithKline plc

12.2.12.              Gerona Corporation

12.2.13.              Gradualist

12.2.14.              ICO Therapeutics

12.2.15.              Aptos Biosciences

12.2.16.              Marina Biotech

12.2.17.              mirage Therapeutics, Inc.

12.2.18.              Synodic, Inc.

12.2.19.              Oncogene Pharmaceuticals Inc.

12.2.20.              Pharm axis Ltd

12.2.21.              Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc.

12.2.22.              RI Pharmaceuticals

12.2.23.              Ionis Pharmaceuticals

12.2.24.              ProQR Therapeutics

12.2.25.              Sterna Biologicals

12.2.26.              Wave Life Sciences

12.2.27.              Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7564
Security Code field cannot be blank!

Frequently Asked Questions

Antisense Oligonucleotide Therapeutics Market is expected to grow at a 15.3% CAGR during the forecast period for 2025-2034

Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Antisense Therapeutics, Sarna Therapeutics, Arrowhead Pharmaceuticals, Atlantic Pharmaceuticals

Antisense Oligonucleotide Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.1 Billion by the year 2034

ASO Generation, Phase of Development, Route of Administration, Type of Therapy, Indications and Drug Type are the key segments of the Antisense Oligon

North America region is leading the Antisense Oligonucleotide Therapeutics Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying